Inhibition of Autophagy Induced by TSA Sensitizes Colon Cancer Cell to Radiation

Overview

Journal Tumour Biol

Publisher Sage Publications

Specialty Oncology

Date 2013 Oct 15

PMID 24122231

Citations 16

Authors

Gang He

Yan Wang

Xueli Pang

Bo Zhang

Affiliations

Soon will be listed here.

Abstract

Radiotherapy is one of the main treatments for clinical cancer therapy. However, its application was limited due to lack of radiosensitivity in some cancers. Trichostatin A (TSA) is a classic histone deacetylases inhibitor (HDACi) that specifically inhibits the biochemical functions of HDAC and is demonstrated to be an active anticancer drug. However, whether it could sensitize colon cancer to radiation is not clear. Our results showed that TSA enhanced the radiosensitivity of colon cancer cells as determined by CCK-8 and clonogenic survival assay. Moreover, apoptotic cell death induced by radiation was enhanced by TSA treatment. Additionally, TSA also induced autophagic response in colon cancer cells, while autophagy inhibition led to cell apoptosis and enhanced the radiosensitivity of colon cancer cells. Our data suggested that inhibition of cytoprotective autophagy sensitizes cancer cell to radiation, which might be further investigated for clinical cancer radiotherapy.

Citing Articles

HDAC-an important target for improving tumor radiotherapy resistance.

Ling R, Wang J, Fang Y, Yu Y, Su Y, Sun W Front Oncol. 2023; 13:1193637.

PMID: 37503317 PMC: 10368992. DOI: 10.3389/fonc.2023.1193637.

Trichostatin A enhances radiosensitivity and radiation-induced DNA damage of esophageal cancer cells.

Wang S, Song M, Zhang B J Gastrointest Oncol. 2021; 12(5):1985-1995.

PMID: 34790366 PMC: 8576220. DOI: 10.21037/jgo-21-560.

Synergistic effect of Chloroquine and Panobinostat in ovarian cancer through induction of DNA damage and inhibition of DNA repair.

Ovejero-Sanchez M, Gonzalez-Sarmiento R, Herrero A Neoplasia. 2021; 23(5):515-528.

PMID: 33930758 PMC: 8100353. DOI: 10.1016/j.neo.2021.04.003.

Regulation of Autophagy in Cells Infected With Oncogenic Human Viruses and Its Impact on Cancer Development.

Vescovo T, Pagni B, Piacentini M, Fimia G, Antonioli M Front Cell Dev Biol. 2020; 8:47.

PMID: 32181249 PMC: 7059124. DOI: 10.3389/fcell.2020.00047.

Epigenetics of colorectal cancer: biomarker and therapeutic potential.

Jung G, Hernandez-Illan E, Moreira L, Balaguer F, Goel A Nat Rev Gastroenterol Hepatol. 2020; 17(2):111-130.

PMID: 31900466 PMC: 7228650. DOI: 10.1038/s41575-019-0230-y.

References

Camphausen K, Tofilon P . Inhibition of histone deacetylation: a strategy for tumor radiosensitization. J Clin Oncol. 2007; 25(26):4051-6. DOI: 10.1200/JCO.2007.11.6202. View

Kondo Y, Kanzawa T, Sawaya R, Kondo S . The role of autophagy in cancer development and response to therapy. Nat Rev Cancer. 2005; 5(9):726-34. DOI: 10.1038/nrc1692. View

Cao Y, Klionsky D . Physiological functions of Atg6/Beclin 1: a unique autophagy-related protein. Cell Res. 2007; 17(10):839-49. DOI: 10.1038/cr.2007.78. View

Liu Y, He G, Wang Y, Guan X, Pang X, Zhang B . MCM-2 is a therapeutic target of Trichostatin A in colon cancer cells. Toxicol Lett. 2013; 221(1):23-30. DOI: 10.1016/j.toxlet.2013.05.643. View

Carafa V, Nebbioso A, Altucci L . Histone deacetylase inhibitors: recent insights from basic to clinical knowledge & patenting of anti-cancer actions. Recent Pat Anticancer Drug Discov. 2010; 6(1):131-45. DOI: 10.2174/157489211793980088. View

Berdasco M, Esteller M . Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev Cell. 2010; 19(5):698-711. DOI: 10.1016/j.devcel.2010.10.005. View

Weichert W, Roske A, Gekeler V, Beckers T, Ebert M, Pross M . Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol. 2008; 9(2):139-48. DOI: 10.1016/S1470-2045(08)70004-4. View

Gore S, Baylin S, Sugar E, Carraway H, Miller C, Carducci M . Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res. 2006; 66(12):6361-9. DOI: 10.1158/0008-5472.CAN-06-0080. View

Rhodes L, Nitschke A, Segar H, Martin E, Driver J, Elliott S . The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells. Oncol Rep. 2011; 27(1):10-6. PMC: 3982613. DOI: 10.3892/or.2011.1488. View

10.

Sy L, Yan S, Lok C, Man R, Che C . Timosaponin A-III induces autophagy preceding mitochondria-mediated apoptosis in HeLa cancer cells. Cancer Res. 2008; 68(24):10229-37. DOI: 10.1158/0008-5472.CAN-08-1983. View

11.

Esteller M . Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet. 2007; 8(4):286-98. DOI: 10.1038/nrg2005. View

12.

Mottet D, Castronovo V . Histone deacetylases: anti-angiogenic targets in cancer therapy. Curr Cancer Drug Targets. 2010; 10(8):898-913. DOI: 10.2174/156800910793358014. View

13.

Weichert W, Roske A, Niesporek S, Noske A, Buckendahl A, Dietel M . Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res. 2008; 14(6):1669-77. DOI: 10.1158/1078-0432.CCR-07-0990. View

14.

Caron C, Boyault C, Khochbin S . Regulatory cross-talk between lysine acetylation and ubiquitination: role in the control of protein stability. Bioessays. 2005; 27(4):408-15. DOI: 10.1002/bies.20210. View

15.

Gammoh N, Lam D, Puente C, Ganley I, Marks P, Jiang X . Role of autophagy in histone deacetylase inhibitor-induced apoptotic and nonapoptotic cell death. Proc Natl Acad Sci U S A. 2012; 109(17):6561-5. PMC: 3340088. DOI: 10.1073/pnas.1204429109. View

16.

Folkvord S, Ree A, Furre T, Halvorsen T, Flatmark K . Radiosensitization by SAHA in experimental colorectal carcinoma models-in vivo effects and relevance of histone acetylation status. Int J Radiat Oncol Biol Phys. 2009; 74(2):546-52. DOI: 10.1016/j.ijrobp.2009.01.068. View

17.

Frew A, Lindemann R, Martin B, Clarke C, Sharkey J, Anthony D . Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. Proc Natl Acad Sci U S A. 2008; 105(32):11317-22. PMC: 2516269. DOI: 10.1073/pnas.0801868105. View

18.

Bolden J, Peart M, Johnstone R . Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006; 5(9):769-84. DOI: 10.1038/nrd2133. View

19.

Ree A, Dueland S, Folkvord S, Hole K, Seierstad T, Johansen M . Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study. Lancet Oncol. 2010; 11(5):459-64. DOI: 10.1016/S1470-2045(10)70058-9. View

20.

Weichert W . HDAC expression and clinical prognosis in human malignancies. Cancer Lett. 2008; 280(2):168-76. DOI: 10.1016/j.canlet.2008.10.047. View